1. Mameli C, Guadagni L, Orso M, et al. Epidemiology of growth hormone deficiency in children and adolescents: a systematic review. Endocrine 2024; 85: 91–98. doi: 10.1007/s12020-024-03778-4.
2.
Iwasaki Y, Nishiyama M, Corcoran D, Araki T. Biological roles of growth hormone/prolactin from an evolutionary perspective. Endocr J 2024; 71: 827–837. doi: 10.1507/endocrj.EJ24-0118.
3.
Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR. Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol (Lausanne) 2021; 12: 637209. doi: 10.3389/fendo.2021.637209.
4.
Zhang J, Guo S, Wang T, Chen Q. Comparison between longacting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency: a systematic review. Sci Rep 2025; 15: 26746. doi: 10.1038/s41598-025-10613-x.
5.
Zhu J, Yuan K, Rana S, et al. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis. Sci Rep 2024; 14: 8061. doi: 10.1038/s41598-024-58616-4.
6.
Kucharska A, Witkowska-Sędek E, Erazmus M, et al. The effects of growth hormone treatment beyond growth promotion in patients with genetic syndromes: a systematic review of the literature. Int J Mol Sci 2024; 25: 10169. doi: 10.3390/ijms251810169.
7.
Al Shaikh A, Daftardar H, Alghamdi AA, et al. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Acta Biomed 2020; 91: 29–40. doi: 10.23750/abm.v91i1.9182.
8.
Aycan Z, Araslı Yılmaz A, Yel S, et al. Evaluation of growth hormone results in different diagnoses and trend over 10 years of follow-up: a single-center experience. J Clin Res Pediatr Endocrinol 2021; 13: 332–341. doi: 10.4274/jcrpe.galenos.2021.2020.0238.
9.
Ferrigno R, Savage MO, Cioffi D, et al. Effects of long-term treatment with recombinant growth hormone on growth outcome in children born small for gestational age: a systematic review. Rev Endocr Metab Disord 2025; 26: 147–159. doi: 10.1007/s11154-024-09911-y.
10.
Backeljauw P, Kanumakala S, Loche S, et al. Safety and effectiveness of recombinant human growth hormone in children with Turner syndrome: data from the PATRO Children Study. Horm Res Paediatr 2021; 94: 133–143. doi: 10.1159/000515875.
11.
Ranke MB. Short- and long-term effects of growth hormone in children and adolescents with GH deficiency. Front Endocrinol (Lausanne) 2021; 12: 720419. doi: 10.3389/fendo.2021.720419.
12.
Kum CD, Rho JG, Park HK, et al. Factors influencing growth hormone therapy effect during the prepubertal period in small for gestational age children without catch-up growth. Ann Pediatr Endocrinol Metab 2021; 26: 31–37. doi: 10.6065/apem.2040096.048.
13.
Tidblad A. The history, physiology and treatment safety of growth hormone. Acta Paediatr 2022; 111: 215–224. doi: 10.1111/apa.15948.
14.
Brinkman JE, Tariq MA, Leavitt L, Sharma S. Physiology, growth hormone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK482141/.
15.
Zhou H, Sun L, Zhang S, et al. Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis. Pituitary 2021; 24: 130–142. doi: 10.1007/s11102-020-01079-3.
16.
Lutski M, Zucker I, Zadik Z, et al. Prevalence of diabetes among children treated with growth hormone in Israel. Diabet Med 2019; 36: 1276–1281. doi: 10.1111/dme.13910.
17.
Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab 2022; 107: 3287–3301. doi: 10.1210/clinem/dgac517.
18.
Dyrka K, Łachut K, Kolesińska Z, et al. Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review. J Pediatr Endocrinol Metab 2025; 38: 796–806. doi: 10.1515/jpem-2025-0057.
19.
Zhao T, Ma Y, Zheng Z, et al. Research progress in abnormal carbohydrate, lipid, and protein metabolism in children with isolated growth hormone deficiency. Front Endocrinol (Lausanne) 2025; 16: 1553008. doi: 10.3389/fendo.2025.1553008.
20.
Hou L, Lin S, Liu Z, et al. Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study. J Pediatr Endocrinol Metab 2024; 37: 892–899. doi: 10.1515/jpem-2024-0189.
21.
Dunger D, Darendeliler F, Kandemir N, et al. What is the evidence for beneficial effects of growth hormone treatment beyond height in short children born small for gestational age? A review of published literature. J Pediatr Endocrinol Metab 2020; 33: 53–70. doi: 10.1515/jpem-2019-0098.
22.
Cho MH, An SJ, Shim YS, et al. Impact of growth hormone therapy on bone and body composition in prepubertal children with idiopathic short stature. J Pediatr Endocrinol Metab 2025; 38: 624–630. doi: 10.1515/jpem-2025-0085.
23.
Kühl AM, Tortorella CCS, Almeida CCB, et al. Growth hormone effect on body composition of children born small for gestational age: a systematic review. J Pediatr (Rio J) 2023; 99: 219–227. doi: 10.1016/j.jped.2022.11.010.
24.
Ferruzzi A, Vrech M, Pietrobelli A, et al. The influence of growth hormone on pediatric body composition: a systematic review. Front Endocrinol (Lausanne) 2023; 14: 1093691. doi: 10.3389/fendo.2023.1093691.
25.
Rosenberg AGW, Passone CGB, Pellikaan K, et al. Growth hormone treatment for adults with Prader-Willi syndrome: a meta-analysis. J Clin Endocrinol Metab 2021; 106: 3068–3091. doi: 10.1210/clinem/dgab406.
26.
Mohamed I, Gautam M, Abosheaishaa H, et al. Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol 2024; 36: 1259–1266. doi: 10.1097/MEG.0000000000002819.
27.
Dutta S, Shah RB, Singhal S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Devel Ther 2023; 17: 1907–1932. doi: 10.2147/DDDT.S409373.
28.
Cristin L, Montini A, Martinino A, et al. The role of growth hormone and insulin growth factor 1 in the development of non-alcoholic steatohepatitis: a systematic review. Cells 2023; 12: 517. doi: 10.3390/cells12040517.
29.
Martínez-Moreno CG, Arámburo C. Growth hormone (GH) and synaptogenesis. Vitam Horm 2020; 114: 91–123. doi: 10.1016/bs.vh.2020.04.001.
30.
Tonkaz GY, Çayır A. Assessment of executive function skills in children with isolated growth hormone deficiency: a cross-sectional study. J Clin Res Pediatr Endocrinol 2024; 16: 177–184. doi: 10.4274/jcrpe.galenos.2024.2023-10-6.
31.
Ding JR, Feng C, Zhang H, et al. Changes in resting-state networks in children with growth hormone deficiency. Brain Connect 2024; 14: 84–91. doi: 10.1089/brain.2023.0059.
32.
Trueba-Timmermans DJ, Grootjen LN, Juriaans AF, et al. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader-Willi syndrome. Eur J Endocrinol 2023; 189: 132–139. doi: 10.1093/ejendo/lvad084.
33.
Grootjen LN, Trueba-Timmermans DJ, Damen L, et al. Long-term growth hormone treatment of children with PWS: the earlier the start, the better the outcomes? J Clin Med 2022; 11: 2496. doi: 10.3390/jcm11092496.
34.
Zaffanello M, Pietrobelli A, Cavarzere P, et al. Complex relationship between growth hormone and sleep in children: insights, discrepancies, and implications. Front Endocrinol (Lausanne) 2023; 14: 1332114. doi: 10.3389/fendo.2023.1332114.
35.
Shukur HH, Hussain-Alkhateeb L, Farholt S, et al. Effects of growth hormone treatment on sleep-related parameters in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2021; 106: e3634–e3643. doi: 10.1210/clinem/dgab300.
36.
Tan YT, Azanan MS, Hng SY, et al. Long-term effect of growth hormone on sleep-disordered breathing in Malaysian children with Prader-Willi syndrome: a retrospective study. J Clin Sleep Med 2024; 20: 1291–1299. doi: 10.5664/jcsm.11140.
37.
Martín-Begué N, Mogas E, Wolley Dod C, et al. Growth hormone treatment and papilledema: a prospective pilot study. J Clin Res Pediatr Endocrinol 2021; 13: 146–151. doi: 10.4274/jcrpe.galenos.2020.2020.0007.
38.
Danowitz M, Grimberg A. Clinical indications for growth hormone therapy. Adv Pediatr 2022; 69: 203–217. doi: 10.1016/j.yapd.2022.03.005.
39.
André J, Zhukouskaya VV, Lambert AS, et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet J Rare Dis 2022; 17: 444. doi: 10.1186/s13023-022-02590-5.
40.
Yuen KCJ. Growth hormone and bone: preclinical and clinical perspectives. Endocr Pract 2025; 31: 1197–1206. doi: 10.1016/j.eprac.2025.07.005.
41.
Zverev S, Tenner ZM, Coladonato C, et al. The rising popularity of growth hormone therapy and ensuing orthopedic complications in the pediatric population: a review. Children (Basel) 2024; 11: 1354. doi: 10.3390/children11111354.
42.
Luo C, Liu S, Li Y, et al. Effect of growth hormone on spinal growth and recombinant human growth hormone on scoliosis. Transl Pediatr 2024; 13: 1849857–1841857. doi: 10.21037/tp-24-180.
43.
Park SJ, Lee KH, Lee CS, et al. Impact of growth hormone treatment on scoliosis development and progression: analysis of 1128 patients with idiopathic short stature. J Pediatr Endocrinol Metab 2021; 34: 243–250. doi: 10.1515/jpem-2020-0393.
44.
Zhang XK, Li X, Shi MY, et al. Impact of growth hormone on scoliosis. Pediatr Discov 2023; 1: e26. doi: 10.1002/pdi3.26.
45.
Castets S, Thomas-Teinturier C, Villanueva C, et al. Diagnosis and management of congenital hypopituitarism in children. Arch Pediatr 2024; 31: 165–171. doi: 10.1016/j.arcped.2024.01.003.
46.
Mittal M, Momtaz D, Gonuguntla R, et al. The effect of human growth hormone treatment on the development of slipped capital femoral epiphysis: a cohort analysis with 6 years of follow-up. J Pediatr Orthop 2024; 44: e344–e350. doi: 10.1097/BPO.0000000000002618.
47.
Shaw KA, Shiver AL, Oakes T, Fletcher ND. Slipped capital femoral epiphysis associated with endocrinopathy: a narrative review. JBJS Rev 2022; 10. doi: 10.2106/JBJS.RVW.21.00188.
48.
Tidblad A, Bottai M, Smedby KE, et al. Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden. Front Endocrinol (Lausanne) 2024; 15: 1360139. doi: 10.3389/fendo.2024.1360139.
49.
Basu R, Boguszewski CL, Kopchick JJ. Growth hormone action as a target in cancer: significance, mechanisms, and possible therapies. Endocr Rev 2025; 46: 224–280. doi: 10.1210/endrev/bnae030.
50.
Boguszewski MCS, Boguszewski CL, Chemaililly W, et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol 2022; 186: P35–P52. doi: 10.1530/EJE-21-1186.
51.
Aversa LS, Cuboni D, Grottoli S, et al. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to real life. J Clin Med 2024; 13: 6079. doi: 10.3390/jcm13206079.
ENGLISH
